Belgrade, SERBIA, Jan. 6 /PRNewswire-FirstCall/ - Hard to Treat Diseases' (HTDS.PK) (www.htdsmedical.com) Slavica Bio Chem operating subsidiary (www.slavicabiochem.com) is proud to report that IBISS research group is invited, as a representative of Serbia, to participate in the 13th Moscow International Salon of Inventions and Innovation Technologies "Archimedes" that is to be held from March 30 to April 2, 2010 in Moscow, Russia. More information can be found at http://eng.archimedes.ru/.
Prof. Dr. Mirjana Stojiljkovic, a Medical Advisor of HTDS, and a team leader of IBISS research group said: "This invitation came from the Inventors Association of Serbia, after the competition for the Best Technological Innovation in Serbia in the year 2009. We are proud that our innovation "Delay of Glial Scar Formation as a Prerequisite of Recovery after Central Nervous System Injury" is well recognized, and chosen to represent Serbian inventors at one of the greatest world contests of Inventions and Innovation Technologies "Archimedes". Just as a reminder, in the contest for the Best Technological Innovation in Serbia in the year 2009, Ministry of Science and Technological Development of Republic of Serbia awarded our NEUROBIOS team the second place of all scientific projects (and the first place for biological science) which competed for this prestigious award, for the establishment of novel therapeutic approach in reducing and delaying of glial scar formation, a major factor in the failure of post-injury neurological recovery after the brain and spinal cord injury.
Prof. Dr. Mirjana Stojiljkovic added: "Last year, the international jury and commission of experts of the Salon "Archimedes" have awarded to participants of the exhibition 235 gold and 226 silver medals, 210 diplomas of Rospatent (Federal service on intellectual property, patents and trade-marks), 250 "Certificates of listeners of the University of inventor" and 1000 diplomas of gratitude and respect for participation in the exhibition "Archimedes-2009", and in that way "Archimedes" is one of the world leading competitions. Salon "Archimedes" allows highlighting and distributing information about the best achievements of advanced minds of mankind, gives an additional impulse to development of the market of intellectual property and attracts new investments into high technology industries. The contest is organized under the auspices of the Russian Federation, Moscow City and the World Intellectual Property Organization (WIPO)."
Additional details and information will be released, via regular news release or Pink Sheets filing service.
To receive future updates via email, including quarterly newsletters and company updates that may not be newsworthy, however important to the reader and followers of the company, please sign up today free at www.minamargroup.com/updates
Safe Harbor Statement
Information in this filing may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases, Inc. that constitute forward-looking statements for purposes of the safe harbor Provision's under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be," "expects," "may affect," "believed," "estimate," "project," and similar words and phrases are intended to identify such forward-looking statements. HTDS Corporation cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases, Inc. is not a guarantee of future performance. None of the information in this filing constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases, Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases, Inc.'s control. In addition to those discussed in Hard to Treat Diseases, Inc.'s press releases, public filings, and statements by Hard to Treat Diseases, Inc.'s management, including, but not limited to, Hard to Treat Diseases, Inc.'s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases, Inc.'s ability to raise additional capital to fund future operations, HTDS Corporation's ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities and, in identifying contracts which match Hard to Treat Diseases, Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases, Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.
SOURCE Hard to Treat Diseases